Wall Street analysts predict that Opiant Pharmaceuticals Inc (NASDAQ:OPNT) will announce earnings of ($0.20) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Opiant Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.04). The business is expected to issue its next earnings report on Tuesday, November 10th.

According to Zacks, analysts expect that Opiant Pharmaceuticals will report full year earnings of ($0.83) per share for the current fiscal year, with EPS estimates ranging from ($1.34) to ($0.33). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($3.90) to $0.40. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Opiant Pharmaceuticals.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Thursday, August 6th. The technology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.26. Opiant Pharmaceuticals had a net margin of 25.32% and a negative return on equity of 2.43%. The firm had revenue of $6.31 million for the quarter, compared to analyst estimates of $6.47 million.

Separately, ValuEngine downgraded shares of Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 1st.

Shares of NASDAQ:OPNT traded down $0.18 on Tuesday, hitting $7.56. The company had a trading volume of 7,033 shares, compared to its average volume of 36,816. Opiant Pharmaceuticals has a 1-year low of $7.35 and a 1-year high of $18.23. The stock has a market cap of $32.19 million, a price-to-earnings ratio of 4.40 and a beta of 0.67. The stock has a 50 day moving average price of $8.16 and a 200 day moving average price of $9.48.

A number of institutional investors and hedge funds have recently bought and sold shares of OPNT. Morgan Stanley lifted its position in Opiant Pharmaceuticals by 27.8% during the first quarter. Morgan Stanley now owns 4,542 shares of the technology company’s stock worth $44,000 after purchasing an additional 989 shares during the period. Fondren Management LP lifted its holdings in shares of Opiant Pharmaceuticals by 18.6% in the first quarter. Fondren Management LP now owns 314,300 shares of the technology company’s stock worth $3,011,000 after acquiring an additional 49,400 shares during the last quarter. Finally, Advisor Group Holdings Inc. bought a new position in shares of Opiant Pharmaceuticals in the first quarter worth about $45,000. 19.32% of the stock is owned by institutional investors and hedge funds.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on Opiant Pharmaceuticals (OPNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.